Understand multiple sclerosis treatment options: A clinical overview of current care

Understanding multiple sclerosis treatment options requires separating care into several related goals: controlling acute relapses, reducing future inflammatory activity, addressing symptoms, preserving function, and monitoring safety over time. Treatment choices are individualized because MS type, disease activity, medical history, and patient preferences influence the balance between benefit and risk.

How treatment is organized

MS care generally includes four components: disease-modifying therapies, treatment for acute relapses, symptom management, and rehabilitation. Disease-modifying therapies aim to reduce relapses, new inflammatory lesions visible on MRI, and the accumulation of disability, but they do not cure MS or repair nerve damage that has already occurred.1

The treatment plan also depends on whether MS is relapsing, progressive, active, or nonactive. Clinically isolated syndrome, relapsing-remitting MS, active secondary progressive MS, and primary progressive MS do not have identical treatment indications. A person with progressive disease and no relapses or new MRI lesions may have fewer applicable disease-modifying options than someone with active inflammatory disease.2

Disease-modifying therapies

Disease-modifying therapies work mainly by reducing immune activity involved in inflammatory attacks on the brain and spinal cord. U.S.-approved options include injectable, oral, and infused medicines. The selection process considers expected effectiveness, administration route, infection risk, laboratory and MRI monitoring, contraindications, tolerability, cost, and personal preferences.3

Two broad prescribing strategies are commonly discussed. An escalation approach begins with a therapy viewed as more moderate in effectiveness and changes treatment if disease activity continues. A higher-efficacy approach uses a stronger therapy earlier when disease features suggest a substantial risk of future activity. Evidence is still developing regarding the optimal strategy, so shared decision-making remains central to treatment selection.4

Options for relapsing MS

People with relapsing forms of MS who have recent clinical relapses or MRI lesion activity are generally considered for disease-modifying treatment. The available medicines differ in mechanism, dosing schedule, route, adverse effects, and required screening. Injectable therapies may involve regular self-administration, oral medicines require adherence and safety monitoring, and infused therapies require clinical administration and observation.5

Highly active MS may lead clinicians to consider therapies such as alemtuzumab, fingolimod, or natalizumab under guideline-based care. Ocrelizumab is approved for relapsing forms of MS and also for eligible people with primary progressive MS. Treatment does not eliminate every relapse or MRI lesion, so response is assessed through symptoms, examinations, imaging, and safety testing rather than by assuming complete disease suppression.3

Primary and secondary progressive disease

Progressive MS requires attention to whether inflammation remains active and whether disability is worsening independently of relapses. Ocrelizumab is an approved option for eligible primary progressive MS, while siponimod is approved for active secondary progressive MS. These approvals do not mean that every person with progressive MS will benefit equally, because disease stage and activity affect expected outcomes.6

Current therapies may provide less benefit for people with slowly worsening progressive MS in the absence of relapses or new MRI lesions. For that reason, care may place greater emphasis on rehabilitation, prevention of complications, mobility support, cognitive strategies, and symptom treatment. Ongoing assessment is important because a previously nonactive course can later show clinical or radiological activity.1

Managing acute relapses

A true relapse results from new, acute focal inflammatory demyelination and may improve more quickly with high-dose corticosteroids. Steroids are not appropriate for every episode of worsening, however. Infection, another systemic illness, sleep deprivation, or other stressors can temporarily worsen old MS symptoms without representing new inflammatory disease.1

Clinical evaluation helps distinguish a relapse from a temporary worsening of established symptoms and determines whether treatment is needed. Severe relapses that respond inadequately to corticosteroids may be considered for plasma exchange. The purpose of relapse treatment is to shorten recovery time and reduce inflammation during the episode, not to replace long-term disease-modifying therapy.8

Symptoms, rehabilitation, and daily function

Symptom management is separate from disease modification because many symptoms require targeted treatment even when inflammatory activity is controlled. Spasticity, neuropathic pain, fatigue, bladder dysfunction, bowel problems, depression, walking difficulty, weakness, and cognitive changes may require medicines, behavioral strategies, assistive devices, or coordinated care from several disciplines.2

Rehabilitation can include physical therapy, occupational therapy, speech therapy, exercise planning, balance training, and strategies for conserving energy or adapting daily activities. These interventions are intended to preserve participation and independence, manage disability, and reduce complications. Smoking cessation, attention to comorbid conditions, and evaluation of medication interactions are also part of comprehensive MS care.7

Monitoring, safety, and shared decisions

Before starting a disease-modifying therapy, clinicians screen for treatment-specific contraindications and establish a monitoring plan. Follow-up may involve clinical examinations, MRI scans, blood tests, infection assessment, and review of adverse effects. Monitoring is necessary because a therapy can be effective against MS activity while also creating risks that require dose changes, switching, or discontinuation.1

Patients and clinicians weigh disease activity against safety, tolerability, administration preferences, pregnancy plans, comorbidities, access, and the practical burden of continued monitoring. Guidelines emphasize an ongoing conversation rather than a one-time decision, including discussion of when treatment should be changed or stopped. An MS-trained neurologist can interpret these factors within the individual clinical context.9

Sources

1. Mowry EM, Okuda DT, Ontaneda D. Treatment of Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology. https://doi.org/10.1212/cont.0000000000001679
2. Merck Manual Professional Edition. Multiple Sclerosis. https://www.merckmanuals.com/en-ca/professional/neurologic-disorders/demyelinating-disorders/multiple-sclerosis-ms
3. American Academy of Neurology guideline summary via Medscape. Disease-Modifying Therapies for Adults With Multiple Sclerosis. https://reference.medscape.com/cc2/p10/guideline-therapies-adults-multiple-sclerosis-2026a10007mu
4. MS in the 21st Century Steering Group. Guiding Multiple Sclerosis Care: An Update to the 2013 Consensus Statement. https://link.springer.com/article/10.1007/s40120-025-00849-0
5. Healio Clinical Guidance. Treatment Options: Multiple Sclerosis. https://www.healio.com/clinical-guidance/multiple-sclerosis/treatment-options-assessment-and-treatment
6. Multiple Sclerosis News Today. Disease-modifying therapies for multiple sclerosis. https://multiplesclerosisnewstoday.com/treatments-that-modify-the-disease-course/
7. National Institute of Neurological Disorders and Stroke. Multiple Sclerosis. https://www.ninds.nih.gov/health-information/disorders/multiple-sclerosis
8. Mayo Clinic. Multiple sclerosis: Diagnosis and treatment. https://www.mayoclinic.org/diseases-conditions/multiple-sclerosis/diagnosis-treatment/drc-20350274
9. Cleveland Clinic. Multiple Sclerosis. https://my.clevelandclinic.org/health/diseases/17248-multiple-sclerosis-ms